

Trading Statement

January – March 2025

*Jean-Yves Parisot (CEO),
Olaf Klinger (CFO)*

29 April 2025



Q1 2025 at a Glance

Key highlights

1		+4.2% organic growth
2		2025 guidance reaffirmed
3		Update on our transformational journey

1

+4.2% organic growth




1 +4.2% organic growth

Group Q1 2025

Organic growth of 4.2 %

Sales development

In €m



Solid start to 2025 with organic growth of 4.2% supported by the strength of diversified, innovation-led portfolio as well as higher volumes across both segments and sustained customer demand

Reported sales rose 2.0% to €1,317 million (Q1 2024: €1,292 million)

Portfolio effect of minus €10m

- Divestment of 51% of the beverage Trading Business in UK, as of March 1, 2024

Currency effects of minus €19 million, attributable to multiple currencies


1 +4.2% organic growth

Taste, Nutrition & Health Q1 2025

Food & Beverage with industry-leading growth rates

Sales development

In €m



Organic growth of 5.9%

- **Food & Beverage achieved industry-leading growth rates**
 - High-single-digit growth across portfolio driven by strong volume growth
 - Business units for savory and sweet applications delivered mid-single-digit organic growth
 - Beverage applications achieved double-digit organic growth
 - EAME (Europe, Africa, Middle East) and Asia/Pacific regions showed particularly strong business growth
- **Pet Food fundamentals remain strong**
 - Continued growth momentum and underlying volume growth in both Palatability and Nutrition


Portfolio effect from divestment of beverage Trading Business, UK in March 2024

Scent & Care Q1 2025

Strong momentum for Fragrance and Aroma Molecules

Sales development

In €m



Organic growth of 1.7%

- **Fragrance** achieved high single-digit organic growth
 - Strong momentum across Fine Fragrances, Consumer Fragrance and Oral Care
 - Particularly robust growth in Latin America, EAME, and Asia/Pacific regions
- **Cosmetic Ingredients** below prior-year period due to very high comparatives in Q1 2024
 - Expected to return to the superior above market growth rates going forward
- **Aroma Molecules** delivered high-single-digit growth
 - Supported by strong momentum and robust demand in North America and Asia/Pacific regions

Conducted strategic assesement of the existing footprint of our Chemicals Production activities.


2

2025 guidance reaffirmed




Outlook

Reaffirming our full year 2025 guidance



Organic sales growth

5 – 7%



Profitability

EBITDA margin

~ 21%



Business Free Cash Flow

% of sales

~ 14%

3

*Update on our
transformational journey*




Our Transformational journey to execute our Strategic roadmap

Positioning Symrise as Unique differentiating player, growing profitably



ONE Symrise Strategy



Transformation updates

PORTFOLIO

- ⇒ **ONE CARE**
Integration of Probi ongoing
- ⇒ **Chemical Production**
Exploring strategic options for Terpene Ingredients

GROWTH

- ⇒ **New products**
Numerous innovative solutions launches

EFFICIENCY

- ⇒ **Procurement & Industrial Operations**
New Operating Model




symrise

*always
inspiring more*

...

Symrise AG

Financial calendar 2025



20 Mai

Annual general meeting

30 July

H1 2025 Financial results

28 October

9M 2025 Trading statement



Contact

Symrise AG

Muehlenfeldstraße 1
37603 Holzminden, Germany

Rene Weinberg

Head of Investor Relations
rene.weinberg@symrise.com

Gresa Latifi

Investor Relations
gresa.latifi@symrise.com

This document contains forward-looking statements, which are based on the current estimates and assumptions by the corporate management of Symrise AG. Future performance and the results actually achieved by Symrise AG and its affiliated companies depend on a number of risks and uncertainties and may therefore differ materially from the forward-looking statements. Many of these factors are outside Symrise's control and cannot be accurately estimated in advance, such as the future economic environment and the actions of competitors and others involved in the marketplace. Symrise neither plans nor undertakes to update any forward-looking statements.